Summit shares shoot up on positive DMD PhII; AstraZeneca and allies back a new incubator/accelerator at Babraham
→ Shares of Oxford-based Summit Therapeutics $SMMT shot up 28% on Thursday morning after rolling out positive biomarker data from a Phase II study of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.